nach oben

Erschienen in:

29.05.2023 | Original Article

Decrease in osteoporotic fracture in the western Kitakyushu region by the STOP-Fx study

verfasst von: Yoshiaki Yamanaka, Satoshi Ikeda, Eiji Hatakeyama, Ken Sabanai, Hiroaki Tanaka, Satoshi Nishida, Yukichi Zenke, Takafumi Tajima, Manabu Tsukamoto, Hinako Obara, Kimiaki Kawano, Akinori Sakai

Erschienen in: Journal of Bone and Mineral Metabolism | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The Seamless Treatment of Osteoporosis against Fractures (STOP-Fx) study was initiated to provide and continue therapeutic interventions for registered patients with osteoporotic fractures.

Materials and methods

Women who visited six hospitals in the western Kitakyushu area for osteoporotic fractures between October 2016 and December 2018 were included in the study. Data collection for primary and secondary outcomes was conducted from October 2018 to December 2020, 2 years after STOP-Fx study enrollment. The primary outcome included the number of surgeries for osteoporotic fractures after the STOP-Fx study intervention, while secondary outcomes were the intervention rate of osteoporosis treatment, incidence and timing of secondary fractures, and factors associated with secondary fractures and loss to follow-up.

Results

Concerning the primary outcome, the number of surgeries for osteoporotic fractures decreased since the STOP-Fx study initiation: 813 in 2017, 786 in 2018, 754 in 2019, 716 in 2020, and 683 in 2021. Regarding the secondary outcome, of the 805 patients enrolled, 445 were available for follow-up at 24 months. Of the 279 patients who were untreated for osteoporosis at enrollment, 255 (91%) were on treatment at 24 months. There were 28 secondary fractures, which were associated with increased tartrate-resistant acid phosphatase-5b and decreased lumbar spine bone mineral density during enrollment in the STOP-Fx study.

Conclusion

As the demographics and medical area served by six hospitals in the western Kitakyushu region have not changed significantly since the STOP-Fx study initiation, the STOP-Fx study may have contributed in decreasing the number of osteoporotic fractures.

Nur mit Berechtigung zugänglich

Kitakyushu city, Japan. https://www.city.kitakyushu.lg.jp/ho-huku/file_0487.html. Accessed 1 Dec 2022 (Japanese)

United Nations, Population Division. https://population.un.org/. Accessed 1 Dec 2022

National Institute of Population and Social Security Research, Simplified inpatient estimates based on population estimates. https://public.tableau.com/views/EstPat2014/sheet2?:embed=y&:showVizHome=no&:showTabs=y&:display_count=y&:display_static_image=y&:bootstrapWhenNotified=true. Accessed 1 Dec 2022 (Japanese)

Iba K, Dohke T, Takada J, Sasaki K, Sonoda T, Hanaka M, Miyano S, Yamashita T (2018) Improvement in the rate of inadequate pharmaceutical treatment by orthopaedic surgeons for the prevention of a second fracture over the last 10 years. J Orthop Sci 23:127–131. https://doi.org/10.1016/j.jos.2017.09.008CrossRefPubMed

Kishimoto H, Maehara M (2015) Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA. Arch Osteoporos 10:231. https://doi.org/10.1007/s11657-015-0231-6CrossRefPubMed

Dell R, Greene D (2010) Is osteoporosis disease management cost effective? Curr Osteoporos Rep 8:49–55. https://doi.org/10.1007/s11914-010-0009-0CrossRefPubMed

Payne RB, Little AJ, Williams RB, Milner JR (1973) Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 4:643–646. https://doi.org/10.1136/bmj.4.5893.643CrossRefPubMedPubMedCentral

Kitakyushu city, Japan. https://www.city.kitakyushu.lg.jp/soumu/file_0373.html. Accessed 5 Feb 2022 (Japanese)

Nogata city, Japan. https://www.city.nogata.fukuoka.jp/shisei/_2656/_2660/_2970.html. Accessed 5 Feb 2022 (Japanese)

10.

Ashiya town, Japan. https://www.town.ashiya.lg.jp/site/jinko/11377.html. Accessed 5 Feb 2022 (Japanese)

11.

Onga town, Japan. https://www.town.onga.lg.jp/soshiki/9/1190.html. Accessed 5 Feb 2022 (Japanese)

12.

Mizumaki town. https://www.town.mizumaki.lg.jp/li/gyosei/080/010/010/150/index.html. Accessed 5 Feb 2022 (Japanese)

13.

British Orthopaedic Association, British Geriatrics Society (2007) The care of patients with fragility fracture, United Kingdom

14.

Japanese orthopaedic association, Osteoporosis Committee. https://www.joa.or.jp/member/committee/osteoporosis/pdf/femur20.pdf. Accessed 1 Dec 2022 (Japanese)

15.

Milliman report. https://jp.milliman.com/-/media/milliman/importedfiles/uploadedfiles/insight/2019/client-report-fracture-care-cost.ashx. Accessed 1 Dec 2022 (Japanese)

16.

Bawa HS, Weick J, Dirschl DR (2015) Anti-osteoporotic therapy after fragility fracture lowers rate of subsequent fracture: analysis of a large population sample. J Bone Joint Surg Am 97:1555–1562. https://doi.org/10.2106/JBJS.N.01275CrossRefPubMed

17.

Myrtle JF, Norman AW (1971) Vitamin D: a cholecalciferol metabolite highly active in promoting intestinal calcium transport. Science 171:79–82. https://doi.org/10.1126/science.171.3966.79CrossRefPubMed

18.

Tähtelä R, Seppänen J, Laitinen K, Katajamäki A, Risteli J, Välimäki MJ (2005) Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide. Osteoporos Int 16:1109–1116. https://doi.org/10.1007/s00198-004-1819-7CrossRefPubMed

19.

Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimäki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Sievänen H, Vuori I, Väänänen HK, Halleen JM (2005) Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20:1804–1812. https://doi.org/10.1359/JBMR.050403CrossRefPubMed

20.

Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, Reid IR, Resch H, Siris E, Uebelhart D, Wang A, Weryha G, Cummings SR (2011) Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 26:530–537. https://doi.org/10.1002/jbmr.251CrossRefPubMed

21.

Hauschka PV, Lian JB, Cole DE, Gundberg CM (1989) Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev 69:990–1047. https://doi.org/10.1152/physrev.1989.69.3.990CrossRefPubMed

22.

Hodges SJ, Akesson K, Vergnaud P, Obrant K, Delmas PD (1993) Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture. J Bone Miner Res 8:1241–1245. https://doi.org/10.1002/jbmr.5650081012CrossRefPubMed

23.

World Health Organization (2003) Prevention and management of osteoporosis. World Health Organ Tech Rep Ser 921:1–164

24.

Kasukawa Y, Miyakoshi N, Ebina T, Aizawa T, Hongo M, Nozaka K, Ishikawa Y, Saito H, Chida S, Shimada Y (2014) Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis. J Bone Miner Metab 32:290–297. https://doi.org/10.1007/s00774-013-0490-5CrossRefPubMed

25.

Hirao M, Hashimoto J, Ando W, Ono T, Yoshikawa H (2008) Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal women. J Bone Miner Metab 26:260–264. https://doi.org/10.1007/s00774-007-0823-3CrossRefPubMed

26.

Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E (2001) Risk of new vertebral fracture in the year following a fracture. JAMA 285:320–323. https://doi.org/10.1001/jama.285.3.320CrossRefPubMed

27.

Iconaru L, Charles A, Baleanu F, Surquin M, Benoit F, Mugisha A, Moreau M, Paesmans M, Karmali R, Rubinstein M, Rozenberg S, Body JJ, Bergmann P (2022) Prediction of an imminent fracture after an index fracture—models derived from the Frisbee cohort. J Bone Miner Res 37:59–67. https://doi.org/10.1002/jbmr.4432CrossRefPubMed

28.

Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 23:CD003376. https://doi.org/10.1002/14651858.CD003376.pub3CrossRef

29.

Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 23:CD001155. https://doi.org/10.1002/14651858.CD001155.pub2CrossRef

30.

Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T (2009) Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study. Osteoporos Int 20:1429–1437. https://doi.org/10.1007/s00198-008-0816-7CrossRefPubMed

31.

Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 3:CD004523. https://doi.org/10.1002/14651858.CD004523.pub3CrossRef

32.

Chesnut CH 3rd, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249. https://doi.org/10.1359/JBMR.040325CrossRefPubMed

33.

Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799–1809. https://doi.org/10.1056/NEJMoa074941CrossRefPubMed

34.

Maricic M, Adachi JD, Sarkar S, Wu W, Wong M, Harper KD (2002) Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med 162:1140–1143. https://doi.org/10.1001/archinte.162.10.1140CrossRefPubMed

35.

Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Shiraki M, Fukunaga M (2014) Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab 99:2599–2607. https://doi.org/10.1210/jc.2013-4175CrossRefPubMedPubMedCentral

36.

Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Yoshikawa H, Nishizawa Y, Fujita T, Shiraki M (2012) Randomized Teriparatide [human parathyroid hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97:3097–3106. https://doi.org/10.1210/jc.2011-3479CrossRefPubMed

37.

Robinson CM, Royds M, Abraham A, McQueen MM, Court-Brown CM, Christie J (2002) Refractures in patients at least forty-five years old. A prospective analysis of twenty-two thousand and sixty patients. J Bone Joint Surg Am 84:1528–1533. https://doi.org/10.2106/00004623-200209000-00004CrossRefPubMed

38.

Hirose D, Ishida K, Nagano Y, Takahashi T, Yamamoto H (2004) Posture of the trunk in the sagittal plane is associated with gait in community-dwelling elderly population. Clin Biomech (Bristol, Avon) 19:57–63. https://doi.org/10.1016/j.clinbiomech.2003.08.005CrossRefPubMed

39.

Takemitsu Y, Harada Y, Iwahara T, Miyamoto M (1988) Miyatake Y (1988) Lumbar degenerative kyphosis Clinical, radiological and epidemiological studies. Spine (Phila Pa 1976) 13:1317–1326CrossRefPubMed

40.

Johansson H, Siggeirsdóttir K, Harvey NC, Odén A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA (2017) Imminent risk of fracture after fracture. Osteoporos Int 28:775–780. https://doi.org/10.1007/s00198-016-3868-0CrossRefPubMed

41.

Hagino H, Uemura Y, Mori S, Sone T, Ohta H, Nakamura T (2021) Risk factors for incident vertebral fractures in osteoporosis pharmacotherapy: a 2-year, prospective, observational study. J Bone Miner Metab 39:668–677. https://doi.org/10.1007/s00774-021-01208-3CrossRefPubMed

42.

Mitchell PJ (2011) Fracture Liaison Services: the UK experience. Osteoporos Int 22:487–494. https://doi.org/10.1007/s00198-011-1702-2CrossRefPubMed

43.

Solomon DH, Patrick AR, Schousboe J, Losina E (2014) The potential economic benefits of improved postfracture care: a cost-effectiveness analysis of a fracture liaison service in the US health-care system. J Bone Miner Res 29:1667–1674. https://doi.org/10.1002/jbmr.2180CrossRefPubMed

44.

Nayak S, Singer A, Greenspan SL (2021) Cost-effectiveness of secondary fracture prevention intervention for Medicare beneficiaries. J Am Geriatr Soc 69:3435–3444. https://doi.org/10.1111/jgs.17381CrossRefPubMedPubMedCentral

Titel: Decrease in osteoporotic fracture in the western Kitakyushu region by the STOP-Fx study
verfasst von: Yoshiaki Yamanaka
Satoshi Ikeda
Eiji Hatakeyama
Ken Sabanai
Hiroaki Tanaka
Satoshi Nishida
Yukichi Zenke
Takafumi Tajima
Manabu Tsukamoto
Hinako Obara
Kimiaki Kawano
Akinori Sakai
Publikationsdatum: 29.05.2023
Verlag: Springer Nature Singapore
Erschienen in: Journal of Bone and Mineral Metabolism / Ausgabe 4/2023
Print ISSN: 0914-8779
Elektronische ISSN: 1435-5604
DOI: https://doi.org/10.1007/s00774-023-01430-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Decrease in osteoporotic fracture in the western Kitakyushu region by the STOP-Fx study